DOCSLIB.ORG

Taqman® Human and Rat Phosphodiesterase Arrays

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Taqman® Human and Rat Phosphodiesterase Arrays TaqMan® Gene Signature Arrays TaqMan® Human and Rat Phosphodiesterase Arrays These arrays are part of a collection of TaqMan® Gene pathway, is released and can act as a signaling molecule in Signature Arrays that enable analysis of hundreds of TaqMan® apoptosis or growth arrest. Gene Expression Assays on a micro fluidic card with minimal Glycerophosphodiester phosphodiesterases (GDPDs) catalyze effort. the hydrolysis of deacylated glycerophospholipids to glycerol Phosphodiesterases are a group of enzymes that cleave a phosphate and alcohol. Members of this family may provide variety of substrates, including phosphodiesterase and a link between phosphoinositide metabolism and G protein pyrophosphate bonds of nucleotides and nucleotide sugars. signal transduction. Five distinct families are included in these arrays: 1) cyclic The TaqMan® Human Phosphodiesterase Gene Signature Array nucleotide phosphodiesterases; 2) nucleotide pyrophosphatase/ contains 43 human assays and five human controls. phosphodiesterases; 3) acid sphingomyelinases; 4) neutral Orthologous genes to the human array are in the Rat membrane sphingomyelin phosphodiesterases, and Phosphodiesterase Array with two exceptions: Pde6g and 5) glycerophosphodiester phosphodiesterases. Gdpd4 are missing and two added controls (Arbp and Ywhaz) The cyclic nucleotide phosphodiesterase (PDE) superfamily are in the rat array. currently includes 24 different genes grouped into 11 different Group Category Description # Human Gene Symbols PDE families. They degrade the second messenger molecules, PDE1 CaM-dependent PDE 3 PDE1A–PDE1C cyclic AMP (cAMP) and cyclic GMP (cGMP). PDEs have an PDE2 cGMP-stimulated PDE 1 PDE2A important role in signal transduction because they regulate PDE3 cGMP-inhibited PDE 2 PDE3A, PDE3B cyclic nucleotide signaling. PDEs are often targets of drugs due PDE4 cAMP-specific PDE 4 PDE4A–PDE4D to their ability to regulate cyclic nucleotide levels, their unique PDE5 cGMP-specific PDE 1 PDE5A tissue distribution, substrate specificity and pharmacological PDE6 Photoreceptor PDE 6 PDE6A–C, PDE6D, PDE6G, PDE6H properties. Inhibitors of PDEs prolong or enhance the effects PDE7 cAMP-specific PDE 2 PDE7A, PDE7B PDE8 cAMP-specific PDE 2 PDE8A, PDE8B of physiological processes mediated by cAMP and cGMP PDE9 cGMP-specific PDE 1 PDE9A providing therapeutic benefits for erectile dysfunction, asthma, PDE10 dual specificity PDE 1 PDE10A heart failure, inflammation and depression. PDE11 dual specificity PDE 1 PDE11A The ectonucleotide pyrophosphatase/phosphodiesterases ENPP ectonucleotide PPase/PDE 7 ENPP1–7 (ENPPs) are a structurally diverse group of enzymes that have SMase sphingomyelin PDE, neutral 2 SMPD2, SMPD3 ASM sphingomyelin PDE, acid-like 3 SMPD1, SMPDL3A, SMPDL3B an extracellular, catalytic site that releases nucleoside 5’- GDPD glycerophosphodiester PDE 6 GDPD1–5, MIR16 monophosphates from nucleotides. There are seven genes in CNP 2’3’-cyclic nucleotide 3’ PDE 1 CNP the family, and increased expression of ENPP1 is associated Controls 5 18S, ACTB, B2M, GAPDH, PPIA with type 2 diabetes. TOTAL 48 The acid sphingomyelinases (ASMs) and neutral membrane References: sphingomyelin phosphodiesterases are enzymes that catalyze PDE Nature 2003, 425:98–102 hydrolysis of sphingomyelin (SM) into ceramide and CNP J Mol Biol 2005, 346:789–800 phosphorylcholine. Three forms of ASMs have been described, ENPP J Biol Chem 2001, 276(2);1361–1368; J Clin Endocrinol Metab 2006, 91(12):4948–52 an intracellular form found in lysosomes and two extracellular GDPD BBRC 2006 Mar 31, 342(1):323–9; Gene 2006 Apr 12, 371(1):144–53 secreted forms. Two neutral SM phophodiesterases have been MIR Gene 2006 Apr 12, 371(1):144–53 studied, a plasma membrane and a Golgi membrane protein. SMase J Biol Chem 2006, 281(23):16157–16167 Ceramide, which is generated by the sphingomyelinase ASM Protein Science 2004, 13:3172–3186 TaqMan® Gene Signature Arrays Gene Signature Array Name # of Targets/Controls Format Pack Size Part Number Human Phosphodiesterase Array 43/5 Format 48 4 arrays/pack 4378705 Rat Phosphodiesterase Array 41/6 Format 48 4 arrays/pack 4378706 Human Phosphodiesterase Array A CNP ENPP1 ENPP2 ENPP3 ENPP4 ENPP5 ENPP6 ENPP7 GDPD1 GDPD2 18S GDPD3 GDPD4 GDPD5 MIR16 PDE10APDE11APDE1A PDE1B PDE1C PDE2A PDE3A PDE3B PDE4A 1 B PDE4B PDE4C PDE4D PDE5A PDE6A PDE6BPDE6C PDE6DPDE6G PDE6HPDE7A PDE7B PDE8A PDE8B PDE9A SMPD1 SMPD2 SMPD3 SMPDL3A SMPDL3B ACTB B2M GAPDH PPIA C CNP ENPP1 ENPP2 ENPP3 ENPP4 ENPP5 ENPP6 ENPP7 GDPD1 GDPD2 18S GDPD3 GDPD4 GDPD5 MIR16 PDE10APDE11APDE1A PDE1B PDE1C PDE2A PDE3A PDE3B PDE4A 2 D PDE4B PDE4C PDE4D PDE5A PDE6A PDE6BPDE6C PDE6DPDE6G PDE6HPDE7A PDE7B PDE8A PDE8B PDE9A SMPD1 SMPD2 SMPD3 SMPDL3A SMPDL3B ACTB B2M GAPDH PPIA E CNP ENPP1 ENPP2 ENPP3 ENPP4 ENPP5 ENPP6 ENPP7 GDPD1 GDPD2 18S GDPD3 GDPD4 GDPD5 MIR16 PDE10APDE11APDE1A PDE1B PDE1C PDE2A PDE3A PDE3B PDE4A 3 F PDE4B PDE4C PDE4D PDE5A PDE6A PDE6BPDE6C PDE6DPDE6G PDE6HPDE7A PDE7B PDE8A PDE8B PDE9A SMPD1 SMPD2 SMPD3 SMPDL3A SMPDL3B ACTB B2M GAPDH PPIA G CNP ENPP1 ENPP2 ENPP3 ENPP4 ENPP5 ENPP6 ENPP7 GDPD1 GDPD2 18S GDPD3 GDPD4 GDPD5 MIR16 PDE10APDE11APDE1A PDE1B PDE1C PDE2A PDE3A PDE3B PDE4A 4 H PDE4B PDE4C PDE4D PDE5A PDE6A PDE6BPDE6C PDE6DPDE6G PDE6HPDE7A PDE7B PDE8A PDE8B PDE9A SMPD1 SMPD2 SMPD3 SMPDL3A SMPDL3B ACTB B2M GAPDH PPIA I CNP ENPP1 ENPP2 ENPP3 ENPP4 ENPP5 ENPP6 ENPP7 GDPD1 GDPD2 18S GDPD3 GDPD4 GDPD5 MIR16 PDE10APDE11APDE1A PDE1B PDE1C PDE2A PDE3A PDE3B PDE4A 5 J PDE4B PDE4C PDE4D PDE5A PDE6A PDE6BPDE6C PDE6DPDE6G PDE6HPDE7A PDE7B PDE8A PDE8B PDE9A SMPD1 SMPD2 SMPD3 SMPDL3A SMPDL3B ACTB B2M GAPDH PPIA K CNP ENPP1 ENPP2 ENPP3 ENPP4 ENPP5 ENPP6 ENPP7 GDPD1 GDPD2 18S GDPD3 GDPD4 GDPD5 MIR16 PDE10APDE11APDE1A PDE1B PDE1C PDE2A PDE3A PDE3B PDE4A 6 L PDE4B PDE4C PDE4D PDE5A PDE6A PDE6BPDE6C PDE6DPDE6G PDE6HPDE7A PDE7B PDE8A PDE8B PDE9A SMPD1 SMPD2 SMPD3 SMPDL3A SMPDL3B ACTB B2M GAPDH PPIA M CNP ENPP1 ENPP2 ENPP3 ENPP4 ENPP5 ENPP6 ENPP7 GDPD1 GDPD2 18S GDPD3 GDPD4 GDPD5 MIR16 PDE10APDE11APDE1A PDE1B PDE1C PDE2A PDE3A PDE3B PDE4A 7 N PDE4B PDE4C PDE4D PDE5A PDE6A PDE6BPDE6C PDE6DPDE6G PDE6HPDE7A PDE7B PDE8A PDE8B PDE9A SMPD1 SMPD2 SMPD3 SMPDL3A SMPDL3B ACTB B2M GAPDH PPIA O CNP ENPP1 ENPP2 ENPP3 ENPP4 ENPP5 ENPP6 ENPP7 GDPD1 GDPD2 18S GDPD3 GDPD4 GDPD5 MIR16 PDE10APDE11APDE1A PDE1B PDE1C PDE2A PDE3A PDE3B PDE4A 8 P PDE4B PDE4C PDE4D PDE5A PDE6A PDE6BPDE6C PDE6DPDE6G PDE6HPDE7A PDE7B PDE8A PDE8B PDE9A SMPD1 SMPD2 SMPD3 SMPDL3A SMPDL3B ACTB B2M GAPDH PPIA 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Port Rat Phosphodiesterase Array A Cnp1 Dpde1 Enpp1 Enpp2 Enpp3 Enpp4 Enpp5 Enpp6 Enpp7 Gdpd1 18S Gdpd2 Gdpd3 Mir16 Pde10a Pde11a Pde1a Pde1b Pde1c Pde2a Pde3a Pde3b Pde4a Pde4b 1 B Pde4d Pde5a Pde6a Pde6b Pde6c Pde6d Pde6h Pde7a Pde7b Pde8a Pde8b Pde9a RGD1559673 Smpd1 Smpd2 Smpd3 Smpdl3a Smpdl3b Actb Arbp Gapdh Ppia Ywhaz B2m C Cnp1 Dpde1 Enpp1 Enpp2 Enpp3 Enpp4 Enpp5 Enpp6 Enpp7 Gdpd1 18S Gdpd2 Gdpd3 Mir16 Pde10a Pde11a Pde1a Pde1b Pde1c Pde2a Pde3a Pde3b Pde4a Pde4b 2 D Pde4d Pde5a Pde6a Pde6b Pde6c Pde6d Pde6h Pde7a Pde7b Pde8a Pde8b Pde9a RGD1559673 Smpd1 Smpd2 Smpd3 Smpdl3a Smpdl3b Actb Arbp Gapdh Ppia Ywhaz B2m E Cnp1 Dpde1 Enpp1 Enpp2 Enpp3 Enpp4 Enpp5 Enpp6 Enpp7 Gdpd1 18S Gdpd2 Gdpd3 Mir16 Pde10a Pde11a Pde1a Pde1b Pde1c Pde2a Pde3a Pde3b Pde4a Pde4b 3 F Pde4d Pde5a Pde6a Pde6b Pde6c Pde6d Pde6h Pde7a Pde7b Pde8a Pde8b Pde9a RGD1559673 Smpd1 Smpd2 Smpd3 Smpdl3a Smpdl3b Actb Arbp Gapdh Ppia Ywhaz B2m G Cnp1 Dpde1 Enpp1 Enpp2 Enpp3 Enpp4 Enpp5 Enpp6 Enpp7 Gdpd1 18S Gdpd2 Gdpd3 Mir16 Pde10a Pde11a Pde1a Pde1b Pde1c Pde2a Pde3a Pde3b Pde4a Pde4b 4 H Pde4d Pde5a Pde6a Pde6b Pde6c Pde6d Pde6h Pde7a Pde7b Pde8a Pde8b Pde9a RGD1559673 Smpd1 Smpd2 Smpd3 Smpdl3a Smpdl3b Actb Arbp Gapdh Ppia Ywhaz B2m I Cnp1 Dpde1 Enpp1 Enpp2 Enpp3 Enpp4 Enpp5 Enpp6 Enpp7 Gdpd1 18S Gdpd2 Gdpd3 Mir16 Pde10a Pde11a Pde1a Pde1b Pde1c Pde2a Pde3a Pde3b Pde4a Pde4b 5 J Pde4d Pde5a Pde6a Pde6b Pde6c Pde6d Pde6h Pde7a Pde7b Pde8a Pde8b Pde9a RGD1559673 Smpd1 Smpd2 Smpd3 Smpdl3a Smpdl3b Actb Arbp Gapdh Ppia Ywhaz B2m K Cnp1 Dpde1 Enpp1 Enpp2 Enpp3 Enpp4 Enpp5 Enpp6 Enpp7 Gdpd1 18S Gdpd2 Gdpd3 Mir16 Pde10a Pde11a Pde1a Pde1b Pde1c Pde2a Pde3a Pde3b Pde4a Pde4b 6 L Pde4d Pde5a Pde6a Pde6b Pde6c Pde6d Pde6h Pde7a Pde7b Pde8a Pde8b Pde9a RGD1559673 Smpd1 Smpd2 Smpd3 Smpdl3a Smpdl3b Actb Arbp Gapdh Ppia Ywhaz B2m M Cnp1 Dpde1 Enpp1 Enpp2 Enpp3 Enpp4 Enpp5 Enpp6 Enpp7 Gdpd1 18S Gdpd2 Gdpd3 Mir16 Pde10a Pde11a Pde1a Pde1b Pde1c Pde2a Pde3a Pde3b Pde4a Pde4b 7 N Pde4d Pde5a Pde6a Pde6b Pde6c Pde6d Pde6h Pde7a Pde7b Pde8a Pde8b Pde9a RGD1559673 Smpd1 Smpd2 Smpd3 Smpdl3a Smpdl3b Actb Arbp Gapdh Ppia Ywhaz B2m O Cnp1 Dpde1 Enpp1 Enpp2 Enpp3 Enpp4 Enpp5 Enpp6 Enpp7 Gdpd1 18S Gdpd2 Gdpd3 Mir16 Pde10a Pde11a Pde1a Pde1b Pde1c Pde2a Pde3a Pde3b Pde4a Pde4b 8 P Pde4d Pde5a Pde6a Pde6b Pde6c Pde6d Pde6h Pde7a Pde7b Pde8a Pde8b Pde9a RGD1559673 Smpd1 Smpd2 Smpd3 Smpdl3a Smpdl3b Actb Arbp Gapdh Ppia Ywhaz B2m 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Port More arrays will be available soon! Register to receive new Gene Signature Array product announcements, or suggest an array at taqmanarray.appliedbiosystems.com For Research Use Only. Not for use in diagnostic procedures. Practice of the patented 5’ Nuclease Process requires a license from Applied Biosystems. The purchase of TaqMan® Human and Rat Phosphodiesterase Arrays includes an immunity from suit under patents specified in the product inserts to use only the amount purchased for the purchaser’s own internal research when used with the separate purchase of an Authorized 5’ Nuclease Core Kit. No other patent rights are conveyed expressly, by implication, or by estoppel. For further information on purchasing licenses contact the Director of Licensing, Applied Biosystems, 850 Lincoln Centre Drive, Foster City, California 94404, USA. The TaqMan® Array is covered by U.S. Patents Nos. 6,514,750, 6,942,837, 7,211,443, and 7,235,406.
Load more

Recommended publications
  • Recombinant Human Phosphodiesterase 4A/PDE4A
    Recombinant Human Phosphodiesterase 4A/PDE4A Catalog Number: 7767-PE DESCRIPTION Source Spodoptera frugiperda, Sf 21 (baculovirus)­derived Pro331­Met723, with an N­terminal Met and a C­terminal 6­His tag Accession # P27815 N­terminal Sequence Pro331 Analysis Predicted Molecular 46 kDa Mass SPECIFICATIONS SDS­PAGE 44­48 kDa, reducing conditions Activity Measured by its ability to convert cAMP to 5'­AMP. The specific activity is >28,000 pmol/min/μg, as measured under the described conditions. Endotoxin Level <0.01 EU per 1 μg of the protein by the LAL method. Purity >95%, by SDS­PAGE under reducing conditions and visualized by Colloidal Coomassie® Blue stain at 5 μg per lane. Formulation Supplied as a 0.2 μm filtered solution in Tris and NaCl. See Certificate of Analysis for details. Activity Assay Protocol Materials l Assay Buffer (1X): 20 mM Tris, 1 mM MgCl2, 1 mM DTT, 0.01538% CHAPS, pH 7.5 l Recombinant Human Phosphodiesterase 4A/PDE4A (rhPDE4A) (Catalog # 7767­PE) l Adenosine 3’,5’­cyclic monophosphate (cAMP) (Sigma, Catalog # A6885) 0.1 M stock in deionized water l Sialyltransferase Activity Kit (Catalog # EA002) l 96­well Clear Plate (Costar, Catalog # 92592) l Plate Reader (Model: SpectraMax Plus by Molecular Devices) or equivalent Assay 1. Dilute 1 mM Phosphate Standard provided by the Sialyltransferase Kit by adding 40 µL of the 1 mM Phosphate Standard to 360 µL of Assay Buffer for a 100 µM stock. 2. Continue standard curve by performing six additional one­half serial dilutions of the 100 µM Phosphate stock in Assay Buffer.
    [Show full text]
  • Functional T Cells Phosphodiesterase 7A-Deficient Mice Have
    Phosphodiesterase 7A-Deficient Mice Have Functional T Cells Guchen Yang, Kim W. McIntyre, Robert M. Townsend, Henry H. Shen, William J. Pitts, John H. Dodd, Steven G. This information is current as Nadler, Murray McKinnon and Andrew J. Watson of October 2, 2021. J Immunol 2003; 171:6414-6420; ; doi: 10.4049/jimmunol.171.12.6414 http://www.jimmunol.org/content/171/12/6414 Downloaded from References This article cites 37 articles, 17 of which you can access for free at: http://www.jimmunol.org/content/171/12/6414.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on October 2, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2003 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Phosphodiesterase 7A-Deficient Mice Have Functional T Cells Guchen Yang,1 Kim W. McIntyre, Robert M. Townsend, Henry H. Shen, William J. Pitts, John H. Dodd, Steven G. Nadler, Murray McKinnon, and Andrew J.
    [Show full text]
  • Inhibiting PDE7A Enhances the Protective Effects of Neural Stem
    Research Article: New Research | Cognition and Behavior Inhibiting PDE7A enhances the protective effects of neural stem cells on neurodegeneration and memory deficits in sevoflurane-exposed mice https://doi.org/10.1523/ENEURO.0071-21.2021 Cite as: eNeuro 2021; 10.1523/ENEURO.0071-21.2021 Received: 19 February 2021 Revised: 21 May 2021 Accepted: 25 May 2021 This Early Release article has been peer-reviewed and accepted, but has not been through the composition and copyediting processes. The final version may differ slightly in style or formatting and will contain links to any extended data. Alerts: Sign up at www.eneuro.org/alerts to receive customized email alerts when the fully formatted version of this article is published. Copyright © 2021 Huang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed. 1 Inhibiting PDE7A enhances the protective effects of neural stem cells on 2 neurodegeneration and memory deficits in sevoflurane-exposed mice 3 Yanfang Huang, Yingle Chen*, Zhenming Kang, Shunyuan Li* 4 Department of Anesthesiology, Quanzhou First Hospital Affiliated to Fujian Medical 5 University, Quanzhou 362000, Fujian, China 6 7 *Corresponding authors 8 Shunyuan Li and Yingle Chen 9 Department of Anesthesiology, Quanzhou First Hospital Affiliated to Fujian Medical 10 University, Quanzhou 362000, Fujian, China 11 Email: [email protected] (Shunyuan Li); [email protected] (Yingle Chen) 12 Tel: 86-18960333666 13 14 15 Running title: Role of PDE7A in neurodegeneration 16 17 1 18 Abstract 19 Sevoflurane is widely used in general anesthesia, especially for children.
    [Show full text]
  • PDE4) Subtypes in Human Primary CD4+ T Cells: Predominant Role of PDE4D This Information Is Current As of September 26, 2021
    Differential Expression and Function of Phosphodiesterase 4 (PDE4) Subtypes in Human Primary CD4+ T Cells: Predominant Role of PDE4D This information is current as of September 26, 2021. Daniel Peter, S. L. Catherine Jin, Marco Conti, Armin Hatzelmann and Christof Zitt J Immunol 2007; 178:4820-4831; ; doi: 10.4049/jimmunol.178.8.4820 http://www.jimmunol.org/content/178/8/4820 Downloaded from References This article cites 53 articles, 24 of which you can access for free at: http://www.jimmunol.org/content/178/8/4820.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 26, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2007 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Differential Expression and Function of Phosphodiesterase 4 :PDE4) Subtypes in Human Primary CD4؉ T Cells) Predominant Role of PDE4D1 Daniel Peter,* S. L. Catherine Jin,† Marco Conti,† Armin Hatzelmann,* and Christof Zitt2* Type 4 phosphodiesterases (PDE4) are critical regulators in TCR signaling by attenuating the negative constraint of cAMP.
    [Show full text]
  • Table S1 the Four Gene Sets Derived from Gene Expression Profiles of Escs and Differentiated Cells
    Table S1 The four gene sets derived from gene expression profiles of ESCs and differentiated cells Uniform High Uniform Low ES Up ES Down EntrezID GeneSymbol EntrezID GeneSymbol EntrezID GeneSymbol EntrezID GeneSymbol 269261 Rpl12 11354 Abpa 68239 Krt42 15132 Hbb-bh1 67891 Rpl4 11537 Cfd 26380 Esrrb 15126 Hba-x 55949 Eef1b2 11698 Ambn 73703 Dppa2 15111 Hand2 18148 Npm1 11730 Ang3 67374 Jam2 65255 Asb4 67427 Rps20 11731 Ang2 22702 Zfp42 17292 Mesp1 15481 Hspa8 11807 Apoa2 58865 Tdh 19737 Rgs5 100041686 LOC100041686 11814 Apoc3 26388 Ifi202b 225518 Prdm6 11983 Atpif1 11945 Atp4b 11614 Nr0b1 20378 Frzb 19241 Tmsb4x 12007 Azgp1 76815 Calcoco2 12767 Cxcr4 20116 Rps8 12044 Bcl2a1a 219132 D14Ertd668e 103889 Hoxb2 20103 Rps5 12047 Bcl2a1d 381411 Gm1967 17701 Msx1 14694 Gnb2l1 12049 Bcl2l10 20899 Stra8 23796 Aplnr 19941 Rpl26 12096 Bglap1 78625 1700061G19Rik 12627 Cfc1 12070 Ngfrap1 12097 Bglap2 21816 Tgm1 12622 Cer1 19989 Rpl7 12267 C3ar1 67405 Nts 21385 Tbx2 19896 Rpl10a 12279 C9 435337 EG435337 56720 Tdo2 20044 Rps14 12391 Cav3 545913 Zscan4d 16869 Lhx1 19175 Psmb6 12409 Cbr2 244448 Triml1 22253 Unc5c 22627 Ywhae 12477 Ctla4 69134 2200001I15Rik 14174 Fgf3 19951 Rpl32 12523 Cd84 66065 Hsd17b14 16542 Kdr 66152 1110020P15Rik 12524 Cd86 81879 Tcfcp2l1 15122 Hba-a1 66489 Rpl35 12640 Cga 17907 Mylpf 15414 Hoxb6 15519 Hsp90aa1 12642 Ch25h 26424 Nr5a2 210530 Leprel1 66483 Rpl36al 12655 Chi3l3 83560 Tex14 12338 Capn6 27370 Rps26 12796 Camp 17450 Morc1 20671 Sox17 66576 Uqcrh 12869 Cox8b 79455 Pdcl2 20613 Snai1 22154 Tubb5 12959 Cryba4 231821 Centa1 17897
    [Show full text]
  • Mechanisms of Action of PDE5 Inhibition in Erectile Dysfunction
    International Journal of Impotence Research (2004) 16, S4–S7 & 2004 Nature Publishing Group All rights reserved 0955-9930/04 $30.00 www.nature.com/ijir Original Research Mechanisms of action of PDE5 inhibition in erectile dysfunction JD Corbin1* 1Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, Tennesse, USA A spinal reflex and the L-arginine–nitric oxide–guanylyl cyclase–cyclic guanosine monophosphate (cGMP) pathway mediate smooth muscle relaxation that results in penile erection. Nerves and endothelial cells directly release nitric oxide in the penis, where it stimulates guanylyl cyclase to produce cGMP and lowers intracellular calcium levels. This triggers relaxation of arterial and trabecular smooth muscle, leading to arterial dilatation, venous constriction, and erection. Phosphodiesterase 5 (PDE5) is the predominant phosphodiesterase in the corpus cavernosum. The catalytic site of PDE5 normally degrades cGMP, and PDE5 inhibitors such as sildenafil potentiate endogenous increases in cGMP by inhibiting its breakdown at the catalytic site. Phosphorylation of PDE5 increases its enzymatic activity as well as the affinity of its allosteric (noncatalytic/GAF domains) sites for cGMP. Binding of cGMP to the allosteric site further stimulates enzymatic activity. Thus phosphorylation of PDE5 and binding of cGMP to the noncatalytic sites mediate negative feedback regulation of the cGMP pathway. International Journal of Impotence Research (2004) 16, S4–S7. doi:10.1038/sj.ijir.3901205 Keywords: phosphodiesterase inhibitors; vasodilator agents; cyclic GMP; impotence; penile erection Introduction the tone of penile vasculature and the smooth muscle of the corpus cavernosum. In primates, including humans, the L-arginine– In recent years, a deeper understanding of the nitric oxide–guanylyl cyclase–cyclic guanosine regulation of penile smooth muscle has led to monophosphate (cGMP) pathway is the key me- greater insight into the physiology of normal erectile chanism of penile erection1–4 (Figure 1).
    [Show full text]
  • Reduced PDE4 Expression and Activity Contributes to Enhanced Catecholamine-Induced Camp Accumulation in Adipocytes from FOXC2 Transgenic Mice
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector FEBS Letters 580 (2006) 4126–4130 Reduced PDE4 expression and activity contributes to enhanced catecholamine-induced cAMP accumulation in adipocytes from FOXC2 transgenic mice Line M. Grønninga,*, George S. Baillieb, Anna Cederbergc, Martin J. Lynchb, Miles D. Houslayb, Sven Enerba¨ckc, Kjetil Taske´na a Biotechnology Centre of Oslo, University of Oslo, P.O. Box 1125 Blindern, 0317 Oslo, Norway b Dvn Biochemistry and Molecular Biology, IBLS, Wolfson Link Building, University of Glasgow, Glasgow G12 8QQ, Scotland, UK c Medical Genetics, Department of Medical Biochemistry, Go¨teborg University, SE 405 30 Go¨teborg, Sweden Received 11 April 2006; revised 14 June 2006; accepted 15 June 2006 Available online 30 June 2006 Edited by Laszlo Nagy diesterase (PDE) inhibitor IBMX to minimize hydrolysis of Abstract Overexpression of forkhead transcription factor FOXC2 in white adipose tissue (WAT) leads to a lean phenotype cAMP by PDEs. Thus, the strongly enhanced and sustained resistant to diet-induced obesity. This is due, in part, to enhanced cAMP response previously observed in FOXC2 transgenic catecholamine-induced cAMP-PKA signaling in FOXC2 trans- adipocytes is most likely a result of the increased expression genic mice. Here we show that rolipram treatment of adipocytes of b-AR receptors, since this would lead to a more profound from FOXC2 transgenic mice did not increase isoproterenol-in- activation of b-AR associated adenylyl cyclases (ACs) and, duced cAMP accumulation to the same extent as in wild type thus, increased generation of cAMP from ATP.
    [Show full text]
  • PDE4A, Active Human Recombinant Protein Expressed in Sf9 Cells
    Catalog # Aliquot Size P92-31G -05 5 µg P92-31G -10 10 µg PDE4A, Active Human recombinant protein expressed in Sf9 cells Catalog # P92-31G Lot # E3321-2 Product Description Specific Activity Recombinant human PDE4A (332-end) was expressed by 1,400,000 baculovirus in Sf9 insect cells using an N-terminal GST tag. The gene accession number is NM_001111307. 1,050,000 Gene Aliases 700,000 350,000 PDE4; DPDE2; PDE46 (RLU) Activity 0 Formulation 3 4.2 5.4 6.6 7.8 9 Protein (ng) Recombinant protein stored in 50mM Tris-HCl, pH 7.5, 150mM NaCl, 10mM glutathione, 0.1mM EDTA, 0.25mM The specific activity of PDE4A was determined to be 1100 nmol DTT, 0.1mM PMSF, 25% glycerol. /min/mg as per activity assay protocol. Storage and Stability Purity o Store product at –70 C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple The purity was determined to be freeze/thaw cycles. >75% by densitometry. Approx. MW 110kDa. Scientific Background PDE4A is a member of the phosphodiesterase family of proteins that play a critical role in regulating intracellular levels of cAMP. In vitro phosphorylation of PDE4A by the PDE4A, Active PKA-catalytic subunit increases the enzyme's sensitivity to Human recombinant protein expressed in Sf9 cells Mg(2+), leading to a 4-fold increase in cAMP hydrolysis without affecting the Km. PDE4 is widely expressed in Catalog # P92-31G brain tumors and promotes their growth and treatment Specific Activity 1100 nmol/min/mg with PDE4A inhibitor Rolipram overcomes tumor resistance and mediates tumor regression (1).
    [Show full text]
  • 6-Methoxypyrrolidinylquinazoline for Imaging of Phosphodiesterase 10A with PET
    Pharmaceuticals 2012, 5, 169-188; doi:10.3390/ph5020169 OPEN ACCESS Pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Article Radiosynthesis and Radiotracer Properties of a 7-(2-[18F]Fluoroethoxy)-6-methoxypyrrolidinylquinazoline for Imaging of Phosphodiesterase 10A with PET Uta Funke 1,*, Winnie Deuther-Conrad 1, Gregor Schwan 2, Aurélie Maisonial 1, Matthias Scheunemann 1, Steffen Fischer 1, Achim Hiller 1, Detlef Briel 2 and Peter Brust 1 1 Institute of Radiopharmacy, Research Site Leipzig, Helmholtz-Zentrum Dresden-Rossendorf, Permoserstraße 15, Leipzig 04318, Germany; E-Mails: [email protected] (W.D.-C.); [email protected] (A.M.); [email protected] (M.S.); [email protected] (S.F.); [email protected] (A.H.); [email protected] (P.B.) 2 Institute of Pharmacy, Universität Leipzig, Brüderstraße 34, Leipzig 04103, Germany; E-Mails: [email protected] (G.S.); [email protected] (D.B.) * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +49-341-235-3695; Fax: +49-341-235-2731. Received: 24 November 2011; in revised form: 18 January 2012 / Accepted: 19 January 2012 / Published: 6 February 2012 Abstract: Phosphodiesterase 10A (PDE10A) is a key enzyme of intracellular signal transduction which is involved in the regulation of neurotransmission. The molecular imaging of PDE10A by PET is expected to allow a better understanding of physiological and pathological processes related to PDE10A expression and function in the brain. The aim of this study was to develop a new 18F-labeled PDE10A ligand based on a 6,7-dimethoxy- 4-pyrrolidinylquinazoline and to evaluate its properties in biodistribution studies.
    [Show full text]
  • Synergistic Targeting of the Regulatory and Catalytic Subunits of Pi3kd in Mature B-Cell Malignancies Jeffrey D
    Published OnlineFirst December 15, 2017; DOI: 10.1158/1078-0432.CCR-17-2218 Cancer Therapy: Preclinical Clinical Cancer Research Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kd in Mature B-cell Malignancies Jeffrey D. Cooney1, An-Ping Lin1, Daifeng Jiang1, Long Wang1, Avvaru N. Suhasini1, Jamie Myers1, ZhiJun Qiu1, Albert Wol€ fler2, Heinz Sill2, and Ricardo C.T. Aguiar1,3,4 Abstract Purpose: Aberrant activation of the B-cell receptor (BCR) is loss-of-function were used to map multiple signaling inter- implicated in the pathogenesis of mature B-cell tumors, a mediaries downstream of the BCR. concept validated in part by the clinical success of inhibitors Results: Roflumilast elevates the intracellular levels of of the BCR-related kinases BTK (Bruton's tyrosine kinase) and cyclic-AMP and synergizes with idelalisib in suppressing PI3Kd. These inhibitors have limitations, including the paucity tumor growth and PI3K activity. Mechanistically, we show of complete responses, acquired resistance, and toxicity. Here, that roflumilast suppresses PI3K by inhibiting BCR-mediated we examined the mechanism by which the cyclic-AMP/PDE4 activation of the P85 regulatory subunit, distinguishing itself signaling axis suppresses PI3K, toward identifying a novel from idelalisib, an ATP-competitive inhibitor of the catalytic mechanism-based combinatorial strategy to attack BCR-depen- P110 subunit. Using genetic models, we linked the PDE4- dency in mature B-cell malignancies. regulated modulation of P85 activation to the oncogenic Experimental
    [Show full text]
  • Effects of PDE4 Pathway Inhibition in Rat Experimental Stroke
    J Pharm Pharm Sci (www.cspsCanada.org) 17(3) 362 - 370, 2014 Effects of PDE4 Pathway Inhibition in Rat Experimental Stroke Fan Yang1, Rachita K. Sumbria2,4, Dong Xue2, Chuanhui Yu2, Dan He2, Shuo Liu1 Annlia Paganini-Hill2, Mark J. Fisher1,2,3 1 Departments of Anatomy & Neurobiology, 2 Neurology,and 3 Pathology & Laboratory Medicine, University of California, Irvine, California; 4 Department of Biopharmaceutical Sciences, School of Pharmacy, Keck Graduate Institute, Claremont, California Received, April 15, 2014; Revised, July 16, 2014; Accepted July 17, 2014; Published, July 17, 2014. ABSTRACT - PURPOSE: The first genomewide association study indicated that variations in the phosphodiesterase 4D (PDE4D) gene confer risk for ischemic stroke. However, inconsistencies among the studies designed to replicate the findings indicated the need for further investigation to elucidate the role of the PDE4 pathway in stroke pathogenesis. Hence, we studied the effect of global inhibition of the PDE4 pathway in two rat experimental stroke models, using the PDE4 inhibitor rolipram. Further, the specific role of the PDE4D isoform in ischemic stroke pathogenesis was studied using PDE4D knockout rats in experimental stroke. METHODS: Rats were subjected to either the ligation or embolic stroke model and treated with rolipram (3mg/kg; i.p.) prior to the ischemic insult. Similarly, the PDE4D knockout rats were subjected to experimental stroke using the embolic model. RESULTS: Global inhibition of the PDE4 pathway using rolipram produced infarcts that were 225% (p<0.01) and 138% (p<0.05) of control in the ligation and embolic models, respectively. PDE4D knockout rats subjected to embolic stroke showed no change in infarct size compared to wild-type control.
    [Show full text]
  • Analyses of PDE-Regulated Phosphoproteomes Reveal Unique and Specific Camp-Signaling Modules in T Cells
    Analyses of PDE-regulated phosphoproteomes reveal unique and specific cAMP-signaling modules in T cells Michael-Claude G. Beltejara, Ho-Tak Laua, Martin G. Golkowskia, Shao-En Onga, and Joseph A. Beavoa,1 aDepartment of Pharmacology, University of Washington, Seattle, WA 98195 Contributed by Joseph A. Beavo, May 28, 2017 (sent for review March 10, 2017; reviewed by Paul M. Epstein, Donald H. Maurice, and Kjetil Tasken) Specific functions for different cyclic nucleotide phosphodiester- to bias T-helper polarization toward Th2, Treg, or Th17 pheno- ases (PDEs) have not yet been identified in most cell types. types (13, 14). In a few cases increased cAMP may even potentiate Conventional approaches to study PDE function typically rely on the T-cell activation signal (15), particularly at early stages of measurements of global cAMP, general increases in cAMP- activation. Recent MS-based proteomic studies have been useful dependent protein kinase (PKA), or the activity of exchange in characterizing changes in the phosphoproteome of T cells under protein activated by cAMP (EPAC). Although newer approaches various stimuli such as T-cell receptor stimulation (16), prosta- using subcellularly targeted FRET reporter sensors have helped glandin signaling (17), and oxidative stress (18), so much of the define more compartmentalized regulation of cAMP, PKA, and total Jurkat phosphoproteome is known. Until now, however, no EPAC, they have limited ability to link this regulation to down- information on the regulation of phosphopeptides by PDEs has stream effector molecules and biological functions. To address this been available in these cells. problem, we have begun to use an unbiased mass spectrometry- Inhibitors of cAMP PDEs are useful tools to study PKA/EPAC- based approach coupled with treatment using PDE isozyme- mediated signaling, and selective inhibitors for each of the 11 PDE – selective inhibitors to characterize the phosphoproteomes of the families have been developed (19 21).
    [Show full text]